Related Experiment Video

Updated: Aug 9, 2026

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
09:52

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis

Published on: March 9, 2018

[A case of resistant pulmonary and cerebral aspergillosis successfully treated with voriconazole]

Eyüp Sabri Uçan1, Vildan Avkan Oğuz, Ozkan Güngör

  • 1Department of Chest Disease, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey.

Tuberkuloz Ve Toraks
|April 15, 2006
PubMed

Insights

Invasive pulmonary aspergillosis (IPA) is a severe fungal infection in immunocompromised individuals. This case highlights successful treatment of cerebral aspergillosis with voriconazole after initial therapy failure.

Area of Science:

  • Medical Mycology
  • Infectious Diseases
  • Neurology

Background:

  • Invasive pulmonary aspergillosis (IPA) is a critical fungal infection in immunocompromised patients, often presenting diagnostic and therapeutic challenges.
  • Cerebral involvement significantly worsens the prognosis of IPA, demanding specialized treatment strategies.

Observation:

  • A patient diagnosed with usual interstitial pneumonia and treated with immunosuppressants presented with neurological symptoms (headache, vision loss).
  • Diagnostic examinations confirmed invasive pulmonary aspergillosis with concurrent cerebral aspergillosis.

Findings:

  • Initial treatment with Amphotericin B lipid complex for both pulmonary and cerebral aspergillosis showed no response.
  • Subsequent therapy with voriconazole, known for its efficacy in cerebral aspergillosis, led to successful patient recovery.

Implications:

  • This case underscores the importance of considering and diagnosing invasive fungal infections, particularly cerebral aspergillosis, in immunocompromised patients with atypical symptoms.
  • Voriconazole emerges as a crucial therapeutic option for cerebral aspergillosis, offering a successful treatment pathway when initial therapies fail.

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Fungal Phylum Ascomycota01:28

Fungal Phylum Ascomycota

Phylum Ascomycota, a major division within the subkingdom Dikarya, comprises a diverse range of fungal species, including both unicellular yeasts and filamentous molds such as Aspergillus and Penicillium. These fungi thrive in a variety of habitats, from aquatic ecosystems to terrestrial environments, playing crucial ecological and economic roles.Morphology and ReproductionThe defining characteristic of Ascomycetes, commonly referred to as sac fungi, is the ascus—a sac-like structure that...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...